Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Centre, Rostock, Germany; Urology Department, University of Rostock, Rostock, Germany.
Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Centre, Rostock, Germany.
Eur Urol Focus. 2018 Jul;4(4):599-607. doi: 10.1016/j.euf.2017.02.009. Epub 2017 Mar 1.
For penile cancer (PC) there are no known molecular predictors of lymphatic spread and/or chemoresistance.
To identify functional biomarkers that can predict malignant progression and treatment responsiveness.
DESIGN, SETTING, AND PARTICIPANTS: We used four patient-derived PC cell lines and measured invasion and capillary tube formation, chemoresponsiveness, and mRNA and protein expression. Data were further validated in E2F1 transcription factor knockdown and overexpression experiments. We quantified E2F1 transcript levels in a set of nonmetastatic tumours (NM), metastasised primary tumours (PT), and lymph node metastases (M) from 24 patients. E2F1 immunohistochemistry was performed in another set of 13 PC biopsies.
Relationships between different parameters were analysed using Student t tests. Transcript levels in patient samples were compared using Mann-Whitney U tests. Significance was set at p<0.05.
In cell lines established from lymph node metastases, E2F1 was more abundantly expressed, pRB was inactivated, and CDK2, CDK4, and cyclins D and E were elevated in comparison to cells from primary PC. Overexpression of E2F1 enhanced migratory capacity and lymphatic endothelial tubule formation, while depletion reduced invasiveness and increased chemosensitivity. VEGFR-3 and VEGF-C and mesenchymal markers were upregulated by high E2F1. E2F1 was clearly upregulated in infiltrative and metastatic primary tumours and metastases (NM vs PT, p<0.05; NM vs M, p<0.0005). E2F1 Quick scores increased from grade I to grade III tumours. A limitation of the study is the small number of patients.
E2F1 is a driver of invasion and lymphatic dissemination and promotes chemoresistance. E2F1-related biomarkers might assist in stratifying PC patients for different treatment regimens.
The availability of penile cancer cell lines allows molecular research on the mechanisms underlying metastasis and chemotherapy. A critical pathway involved in both features has been identified and may lead to better patient stratification for treatment selection.
目前尚无已知的阴茎癌(PC)淋巴扩散和/或化疗耐药的分子预测因子。
确定可预测恶性进展和治疗反应的功能生物标志物。
设计、设置和参与者:我们使用了 4 个人源 PC 细胞系,测量了侵袭和毛细血管形成、化疗反应以及 mRNA 和蛋白表达。在 E2F1 转录因子敲低和过表达实验中进一步验证了数据。我们在 24 名患者的一组非转移性肿瘤(NM)、转移性原发性肿瘤(PT)和淋巴结转移(M)中定量了 E2F1 转录本水平。在另一组 13 例 PC 活检中进行了 E2F1 免疫组织化学检测。
使用学生 t 检验分析不同参数之间的关系。使用 Mann-Whitney U 检验比较患者样本中的转录本水平。显著性设为 p<0.05。
在来自淋巴结转移的细胞系中,E2F1 的表达更为丰富,pRB 失活,CDK2、CDK4 和细胞周期蛋白 D 和 E 升高,与来自原发性 PC 的细胞相比。E2F1 的过表达增强了迁移能力和淋巴管内皮小管形成,而耗竭则降低了侵袭性并增加了化疗敏感性。VEGFR-3 和 VEGF-C 以及间充质标志物被高 E2F1 上调。E2F1 在侵袭性和转移性原发性肿瘤和转移灶中明显上调(NM 与 PT,p<0.05;NM 与 M,p<0.0005)。E2F1 Quick 评分从 I 级增加到 III 级肿瘤。该研究的一个局限性是患者数量较少。
E2F1 是侵袭和淋巴扩散的驱动因素,并促进化疗耐药。E2F1 相关生物标志物可能有助于为不同的治疗方案对 PC 患者进行分层。
阴茎癌细胞系的可用性允许对转移和化疗的机制进行分子研究。已确定涉及这两个特征的关键途径,这可能导致更好地为患者分层以选择治疗方案。